Table 6.
Overall survival rates categorized by menopausal status and adjuvant therapy
| 3-Year OS (%) | 5-Year OS (%) | 6-Year OS (%) | 7-Year OS (%) | |
|---|---|---|---|---|
| CHT + ET + Trastuzumab | ||||
| Premenopausal (n = 115, 8.5 %) | 98.9 | 97.2 | 97.2 | 97.2 |
| Postmenopausal (n = 170, 3.5 %) | 96.6 | 93.1 | 93.1 | 86.9 |
| CHT + ET | ||||
| Premenopausal (n = 716, 52.9 %) | 97.1 | 95.6 | 94.5 | 92.7 |
| Postmenopausal (n = 1255, 26.2 %) | 95.9 | 89.9 | 87.0 | 84.5 |
| ET | ||||
| Premenopausal (n = 343, 25.3 %) | 99.0 | 96.9 | 96.5 | 95.3 |
| Postmenopausal (n = 2670, 55.7 %) | 93.9 | 87.8 | 84.8 | 81.7 |
| CHT | ||||
| Premenopausal (n = 96, 7.1 %) | 92.7 | 83.7 | 77.6 | 77.6 |
| Postmenopausal (n = 172, 3.6 %) | 80.5 | 75.9 | 74.9 | 72.4 |
| No adjuvant therapy | ||||
| Premenopausal (n = 84, 6.2 %) | 94.1 | 90.8 | 73.1 | 73.1 |
| Postmenopausal (n = 530, 11.0 %) | 79.2 | 68.8 | 63.5 | 58.9 |
Premenopausal patients: n = 1354
Postmenopausal patients: n = 4797
Total: n = 6151